Which diuretic is preferred for a hypertensive patient with chronic kidney disease and an estimated GFR of 52 mL/min/1.73 m²?

Thiazide-Like Diuretics (Chlorthalidone or Indapamide) Are Preferred for HTN with CKD Stage 3a (eGFR 52)

For a patient with hypertension and CKD with an eGFR of 52 mL/min/1.73 m², thiazide-like diuretics (chlorthalidone or indapamide) are the preferred diuretic choice over thiazide-type diuretics (hydrochlorothiazide) or loop diuretics. 1

Rationale and Evidence Hierarchy

The 2025 AHA/ACC hypertension guidelines explicitly recommend thiazide-like diuretics (chlorthalidone or indapamide) as part of first-line triple therapy for hypertension, which should include an ACE inhibitor or ARB, a calcium channel blocker, and a thiazide-like diuretic 1. This recommendation supersedes older teaching that thiazides become ineffective at lower GFR levels.

Why Thiazide-Like Over Thiazide-Type?

• Superior BP reduction: Chlorthalidone and indapamide provide greater blood pressure reduction compared to hydrochlorothiazide (HCTZ) 1
• Enhanced cardiovascular protection: These agents offer additional cardiovascular benefits, particularly in patients with previous MI or stroke 1
• Maintained effectiveness in CKD: Recent evidence demonstrates that thiazide-like diuretics remain effective even in advanced CKD (stages 3b-4) 2

Why Not Loop Diuretics at This eGFR?

At an eGFR of 52 mL/min/1.73 m² (CKD stage 3a), loop diuretics are not the preferred choice. The traditional teaching that "high-ceiling" loop diuretics are required in renal impairment has been challenged 3. Loop diuretics should be reserved for:

• Volume overload requiring more aggressive diuresis
• More advanced CKD (typically eGFR <30 mL/min/1.73 m²)
• Resistant hypertension despite optimal therapy

Clinical Algorithm for Diuretic Selection

For eGFR 45-60 mL/min/1.73 m² (CKD Stage 3a):

1. First choice: Chlorthalidone (12.5-25 mg daily) or indapamide (1.25-2.5 mg daily)
2. Combine with ACE inhibitor/ARB and calcium channel blocker as baseline triple therapy 1
3. Monitor potassium and creatinine within 2-4 weeks 4

For resistant hypertension (BP uncontrolled on triple therapy):

• Add spironolactone (25-50 mg daily) as fourth-line agent if eGFR ≥45 mL/min/1.73 m² 1
• Monitor closely for hyperkalemia (occurs in 4-40% of patients) 1

For eGFR <45 mL/min/1.73 m² (CKD Stage 3b or worse):

• Thiazide-like diuretics still effective 2
• Consider loop diuretics if volume overload present
• Chlorthalidone remains an option even in stage 4 CKD based on CLICK trial data 5

Important Caveats and Monitoring

Electrolyte Monitoring

• Hypokalemia risk: Chlorthalidone carries higher risk of hypokalemia compared to HCTZ (8.9% vs 6.9%) 6
• Check potassium, sodium, and creatinine within 2-4 weeks of initiation
• Monitor for hyponatremia, particularly with higher doses 7

Kidney Function Considerations

• Expect mild, reversible decrease in eGFR with diuretic initiation 7
• Discontinue if creatinine rises >30% within 4 weeks (similar to RAS inhibitor guidance) 4
• Despite lower diuretic clearance at reduced eGFR, BP-lowering effects are maintained 7

Combination Therapy Benefits

• Chlorthalidone can mitigate hyperkalemia risk when used with spironolactone, enabling combination therapy in resistant hypertension 5
• This requires careful BP and kidney function monitoring to prevent adverse events 5

Common Pitfalls to Avoid

1. Don't reflexively switch to loop diuretics at eGFR 52—thiazide-like diuretics remain effective and preferred
2. Don't use HCTZ instead of chlorthalidone/indapamide—the thiazide-like agents provide superior outcomes 1
3. Don't forget dietary sodium restriction—this enhances diuretic effectiveness and RAS inhibitor response 5
4. Don't add spironolactone without checking baseline potassium—hyperkalemia is common and can be dangerous 1